In summary, we provide novel evidence on a widely used biomarker, namely, p53 immunostaining, as a bridging element between a systemic indicator of the glycemic body asset (fasting glucose) and treatment outcomes in a relatively small historic cohort of non diabetic, HER2 positive breast cancer patients treated with trastuzumab. Here, ERBB2 is linked to breast cancer.